Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | GPX4 | P36969 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20892779 | 1.00 | BTK (0.40) | BTKPDE4BGPX4DPP4DPP8 | |
| SCHEMBL20892883 | 0.87 | GPX4 (0.34) | BTKPDE4BGPX4 | |
| SCHEMBL19353417 | 0.82 | BTK (0.42) | BTKPDE4BGPX4DPP8DPP7 | |
| SCHEMBL19353418 | 0.82 | BTK (0.42) | BTKPDE4BGPX4DPP8DPP7 | |
| SCHEMBL19353422 | 0.82 | BTK (0.42) | BTKPDE4BGPX4DPP8DPP7 | |
| SCHEMBL20892778 | 0.79 | BTK (0.41) | BTKPDE4BGPX4DPP8DPP7 | |
| SCHEMBL17522138 | 0.78 | PIK3CD (0.43) | DPP4DPP8DPP7DPP9MEN1 | |
| SCHEMBL17522201 | 0.78 | PIK3CD (0.43) | DPP4DPP8DPP7DPP9MEN1 | |
| SCHEMBL17522199 | 0.78 | PIK3CD (0.43) | DPP4DPP8DPP7DPP9MEN1 | |
| SCHEMBL20892777 | 0.77 | BTK (0.42) | BTKPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS BIOPHARMACEUTICALS, LTD. (KY) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885PDE4B 993/4885GPX4 3181/4885 |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885PDE4B 993/4885GPX4 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.